(Q51381776)

English

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.

scientific article published in February 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21235696

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes. (English)

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21235696

type 2 diabetes

0 references

0 references

author name string

K H Yoon

1

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21235696

G R Shockey

2

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21235696

R Teng

3

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21235696

G T Golm

4

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21235696

P R Thakkar

5

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21235696

A G Meehan

6

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21235696

D E Williams-Herman

7

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21235696

K D Kaufman

8

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21235696

J M Amatruda

9

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21235696

H Steinberg

10

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21235696

publication date

1 February 2011

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21235696

International Journal of Clinical Practice

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21235696

65

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21235696

2

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21235696

154-164

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21235696

Evaluation of risk factors for development of complications in Type II diabetes in Europe

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

It's time to overcome clinical inertia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

The role of gut hormones in glucose homeostasis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Thiazolidinediones improve beta-cell function in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Thiazolidinediones

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Pathogenesis of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Basal and dynamic proinsulin-insulin relationship to assess beta-cell function during OGTT in metabolic disorders.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

1,5-Anhydroglucitol reflects postprandial hyperglycemia and a decreased insulinogenic index, even in subjects with prediabetes and well-controlled type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

The Efficiency of Some Nonparametric Competitors of the t-Test

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

The Importance of -Cell Failure in the Development and Progression of Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02589.X

21 January 2018

Identifiers

10.1111/J.1742-1241.2010.02589.X

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21235696

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21235696

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51381776&oldid=933053264"